Poseida: Roche Acquires Poseida Therapeutics at a 215% Premium
Deal News | Nov 26, 2024 | Aescap Venture Management BV
Roche announced the acquisition of Poseida Therapeutics, a portfolio company of Aescap Genetics, for $9 per share. This price represents a 215% premium over the previous day's closing price of $2.86. In addition to the share price, Poseida shareholders will receive contingent value rights (CVR) amounting to $4, payable upon the achievement of certain future milestones. The total acquisition cost is $1.5 billion. Aescap Genetics had initiated its investment in Poseida Therapeutics in August, with the intention of increasing its stake from 1% to 4% of its portfolio. This acquisition from Roche—made earlier than anticipated by Aescap—leverages Poseida's advancements in next-generation allogeneic CAR-T cancer treatments, demonstrating notable improvements over existing therapies from competitors like J&J, Gilead, and BMS. Apart from its stake in Poseida, Aescap maintains a diversified investment portfolio, holding 22 companies that include other allogeneic CAR-T therapy developers.
Sectors
- Biotechnology
- Healthcare
- Pharmaceuticals
Geography
- United States – Poseida Therapeutics is based in San Diego, making the US a significant geography for the acquisition.
- Europe – Aescap Venture Management BV, the PE firm involved, is based in Europe, showing geographical ties to the transaction.
- Switzerland – Roche, the acquirer, is headquartered in Switzerland, making it relevant to the geographical classification.
Industry
- Biotechnology – This industry involves the development of therapeutics, including CAR-T treatments like those developed by Poseida Therapeutics.
- Healthcare – Focuses on providing medical products and treatment solutions, relevant to Poseida's advanced cancer therapies.
- Pharmaceuticals – Roche's acquisition aligns with typical industry activities involving drug development and therapeutics commercialization.
Financials
- $1.5 billion – Total acquisition price for Poseida Therapeutics by Roche.
- 215% – Premium over Poseida's previous closing share price paid by Roche.
- $9 per share – Acquisition price per share offered by Roche.
- $4 – Contingent Value Rights (CVR) offered to Poseida shareholders, contingent upon future milestones.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Poseida Therapeutics | Target Company | Company | San Diego-based biotech firm engaged in developing next-generation allogeneic CAR-T cancer treatments. |
| Aescap Venture Management BV | PE Firm | Company | European private equity firm involved in the biotech sector with investments in allogeneic CAR-T therapies. |
| Roche | Bidding Company | Company | Multinational healthcare company based in Switzerland that is acquiring Poseida Therapeutics. |